Characterization and Solubilization of Pyrrole−Imidazole Polyamide Aggregates
Abstract
To optimize the biological activity of pyrrole–imidazole polyamide DNA-binding molecules, we characterized the aggregation propensity of these compounds through dynamic light scattering and fractional solubility analysis. Nearly all studied polyamides were found to form measurable particles 50–500 nm in size under biologically relevant conditions, while HPLC-based analyses revealed solubility trends in both core sequences and peripheral substituents that did not correlate with overall ionic charge. The solubility of both hairpin and cyclic polyamides was increased upon addition of carbohydrate solubilizing agents, in particular, 2-hydroxypropyl-β-cyclodextrin (HpβCD). In mice, the use of HpβCD allowed for improved injection conditions and subsequent investigations of the availability of polyamides in mouse plasma to human cells. The results of these studies will influence the further design of Py-Im polyamides and facilitate their study in animal models.
Additional Information
© 2012 American Chemical Society. ACS AuthorChoice. Received: March 20, 2012. Publication Date (Web): May 18, 2012. We thank Dr. Jennifer Keefe (California Institute of Technology) and Sigrid Kuebler (Wyatt Technology Corporation) for assistance with DLS experimentation and data analysis and Dr. Adam Urbach (Trinity University) for helpful discussions. A.E.H. thanks the California Tobacco-Related Disease Research Program (19FT-0105) and the NIH (NRSA number 1F32CA156833) for postdoctoral support. J.A.R. is grateful to the Alexander von Humboldt foundation for the award of a Feodor Lynen postdoctoral fellowship. J.L.M. acknowledges the American Cancer Society for a postdoctoral fellowship (PF-10-015-01-CDD). D.C.M. thanks the National Institutes of Health for a Cellular, Biochemical, and Molecular Sciences Predoctoral Research training grant (5T32GM007616). This work was supported by the Ellison Medical Foundation (AG-SS-2256-09) and NIH grants (GM27681, GM51747). The authors declare no competing financial interest.Attached Files
Published - Hargrove2012p18812J_Med_Chem.pdf
Supplemental Material - jm300380a_si_001.pdf
Files
Name | Size | Download all |
---|---|---|
md5:24f2c21acf26885355c74edb67b4d9cf
|
2.0 MB | Preview Download |
md5:62e00ff77581cc1121bc0aaeb556a68f
|
5.1 MB | Preview Download |
Additional details
- PMCID
- PMC3375050
- Eprint ID
- 32460
- Resolver ID
- CaltechAUTHORS:20120716-095438604
- California Tobacco-Related Disease Research Program
- 19FT-0105
- NIH Postdoctoral Fellowship
- 1F32CA156833
- Alexander von Humboldt Foundation
- American Cancer Society
- PF-10-015-01-CDD
- NIH
- 5T32GM007616
- Ellison Medical Foundation
- AG-SS-2256-09
- NIH
- GM-27681
- NIH
- GM-51747
- Created
-
2012-07-16Created from EPrint's datestamp field
- Updated
-
2021-11-09Created from EPrint's last_modified field